Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Conditions
Brief summary
Phase Ib: Explore the safety and tolerability of BL-M07D1 to further define RP2D in a variety of solid tumors, including locally advanced or metastatic urinary and gastrointestinal tumors. Phase II: To explore the efficacy of BL-M07D1 in patients with a variety of solid tumors including locally advanced or metastatic HER2-positive/low-expressing urinary and gastrointestinal tumors.
Interventions
DRUGBL-M07D1
BL-M07D1 was administered by intravenous infusion every 3 weeks in 3-week cycles.
Sponsors
Sichuan Baili Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Voluntarily sign the informed consent form and comply with the protocol requirements; 2. No gender restrictions; 3. Age: ≥18 years and ≤75 years; 4. Expected survival time ≥3 months; 5. Patients with unresectable locally advanced or metastatic HER2-positive/low-expressing urological and digestive system tumors, as well as other solid tumors; 6. Agree to provide archived tumor tissue specimens or fresh tissue samples from primary or metastatic lesions within the past 2 years; 7. Must have at least one measurable lesion as defined by RECIST v1.1; 8. ECOG performance status score of 0 or 1; 9. Toxicity from prior anti-tumor therapy has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0; 10. No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%; 11. Organ function levels must meet the requirements; 12. Coagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5 × ULN; 13. Urine protein ≤2+ or ≤1000 mg/24h; 14. Albumin ≥30 g/L; 15. For premenopausal women with childbearing potential, a pregnancy test (serum/urine) must be performed within 7 days before starting treatment, and the result must be negative; they must not be breastfeeding. All enrolled patients (regardless of gender) must use adequate barrier contraception throughout the treatment period and for 7 months after treatment ends.
Exclusion criteria
1. Received chemotherapy, biological therapy, immunotherapy, or other antitumor treatments within 4 weeks or 5 half-lives prior to the first dose; 2. Previously treated with ADC drugs containing camptothecin derivatives as payloads; 3. History of severe cardiovascular or cerebrovascular diseases; 4. Active autoimmune or inflammatory diseases; 5. History of other malignancies within 5 years prior to the first dose; 6. Thrombotic events requiring therapeutic intervention within 6 months before screening; 7. Patients with significant pleural/peritoneal/pelvic effusion or pericardial effusion, or those with symptomatic effusion, or poorly controlled effusion; 8. Poorly controlled hypertension despite antihypertensive medication; 9. Current interstitial lung disease, drug-induced interstitial pneumonitis, radiation pneumonitis requiring steroid treatment, or history of these conditions; 10. Patients with primary central nervous system (CNS) tumors or CNS metastases that failed local treatment; 11. History of hypersensitivity to recombinant humanized antibodies or human-mouse chimeric antibodies, or any excipients of BL-M07D1; 12. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation; 13. Positive for human immunodeficiency virus (HIV) antibodies, active tuberculosis, or active hepatitis C virus (HCV) infection; 14. Active hepatitis B virus (HBV) infection (exclusion criterion); 15. Severe infection requiring systemic treatment within 4 weeks before the first dose of the study drug; 16. Participation in another clinical trial within 4 weeks before the first dose; 17. Pregnant or lactating women; 18. Any other condition deemed unsuitable for participation in this clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase Ib: Recommended Phase II Dose (RP2D) | Up to approximately 24 months | The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study. |
| Phase II: Objective response rate (ORR) | Up to approximately 24 months | ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase Ib/II: Disease control rate (DCR) | Up to approximately 24 months | The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\]). |
| Phase Ib/II: Duration of response (DOR) | Up to approximately 24 months | The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first. |
| Phase II: Progression-free survival (PFS) | Up to approximately 24 months | The PFS is defined as the time from the first dose of medication to disease progression or death, whichever occurred first. |
| Phase Ib/II: Cmax | Up to approximately 24 months | Maximum serum concentration (Cmax) of BL-M07D1 will be investigated. |
| Phase Ib/II: Tmax | Up to approximately 24 months | Time to maximum serum concentration (Tmax) of BL-M07D1 will be investigated. |
| Phase Ib/II: Treatment-Emergent Adverse Event (TEAE) | Up to approximately 24 months | TEAE is defined as any adverse and unexpected change in body structure, function, or chemistry or any exacerbation of an existing condition (i.e., any clinically significant adverse change in frequency and/or intensity) during treatment. The type, frequency, and severity of TEAE will be assessed during treatment. |
| Phase Ib: AUC0-t | Up to approximately 24 months | Blood concentration - Area under time line. |
| Phase Ib: CL | Up to approximately 24 months | The serum clearance rate of BL-M07D1 per unit time will be investigated. |
| Phase Ib/II: Ctrough | Up to approximately 24 months | Ctrough is defined as the lowest serum concentration of BL-M07D1 prior to the next dose will be administered. |
| Phase Ib/II: Anti-drug antibody (ADA) | Up to approximately 24 months | Frequency and titer of anti-BL-M07D1 antibody (ADA) will be evaluated. |
| Phase Ib: T1/2 | Up to approximately 24 months | Half-life (T1/2) of BL-M07D1 will be investigated. |
| Phase Ib: Objective response rate (ORR) | Up to approximately 24 months | ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1. |
Countries
China
Contacts
Primary ContactSa Xiao, PHD
Outcome results
None listed